NYSE:OMI

Owens & Minor Competitors

$37.57
-0.19 (-0.50 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$36.94
Now: $37.57
$38.15
50-Day Range
$30.34
MA: $36.17
$38.48
52-Week Range
$6.38
Now: $37.57
$39.45
Volume608,761 shs
Average Volume1.23 million shs
Market Capitalization$2.76 billion
P/E RatioN/A
Dividend Yield0.03%
Beta0.26

Competitors

Owens & Minor (NYSE:OMI) Vs. ICLR, RDY, BHC, CGC, PEN, and PRAH

Should you be buying OMI stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Owens & Minor, including ICON Public (ICLR), Dr. Reddy's Laboratories (RDY), Bausch Health Companies (BHC), Canopy Growth (CGC), Penumbra (PEN), and PRA Health Sciences (PRAH).

ICON Public (NASDAQ:ICLR) and Owens & Minor (NYSE:OMI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Institutional & Insider Ownership

81.7% of ICON Public shares are held by institutional investors. Comparatively, 73.0% of Owens & Minor shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Comparatively, 2.2% of Owens & Minor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ICON Public and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICON Public11.95%21.42%11.85%
Owens & Minor-0.72%18.07%2.26%

Risk and Volatility

ICON Public has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for ICON Public and Owens & Minor, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICON Public04702.64
Owens & Minor05402.44

ICON Public currently has a consensus target price of $219.90, suggesting a potential upside of 7.55%. Owens & Minor has a consensus target price of $27.2778, suggesting a potential downside of 27.39%. Given ICON Public's stronger consensus rating and higher probable upside, research analysts plainly believe ICON Public is more favorable than Owens & Minor.

Earnings and Valuation

This table compares ICON Public and Owens & Minor's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICON Public$2.81 billion3.91$373.99 million$6.8829.72
Owens & Minor$9.21 billion0.30$-62,370,000.00$0.5667.09

ICON Public has higher earnings, but lower revenue than Owens & Minor. ICON Public is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Summary

ICON Public beats Owens & Minor on 13 of the 14 factors compared between the two stocks.

Owens & Minor (NYSE:OMI) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Earnings and Valuation

This table compares Owens & Minor and Dr. Reddy's Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Owens & Minor$9.21 billion0.30$-62,370,000.00$0.5667.09
Dr. Reddy's Laboratories$2.32 billion4.67$259 million$2.7923.30

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Owens & Minor. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Owens & Minor and Dr. Reddy's Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Owens & Minor05402.44
Dr. Reddy's Laboratories00403.00

Owens & Minor presently has a consensus price target of $27.2778, suggesting a potential downside of 27.39%. Dr. Reddy's Laboratories has a consensus price target of $70.00, suggesting a potential upside of 7.68%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Owens & Minor.

Risk and Volatility

Owens & Minor has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Profitability

This table compares Owens & Minor and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Owens & Minor-0.72%18.07%2.26%
Dr. Reddy's Laboratories8.23%16.33%10.79%

Insider & Institutional Ownership

73.0% of Owens & Minor shares are owned by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.2% of Owens & Minor shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dividends

Owens & Minor pays an annual dividend of $0.01 per share and has a dividend yield of 0.0%. Dr. Reddy's Laboratories pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Owens & Minor pays out 1.8% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 9.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Owens & Minor has raised its dividend for 1 consecutive years.

Summary

Dr. Reddy's Laboratories beats Owens & Minor on 10 of the 16 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Owens & Minor (NYSE:OMI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Institutional and Insider Ownership

62.9% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 73.0% of Owens & Minor shares are owned by institutional investors. 12.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 2.2% of Owens & Minor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Bausch Health Companies and Owens & Minor, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies14702.50
Owens & Minor05402.44

Bausch Health Companies currently has a consensus target price of $32.5833, suggesting a potential upside of 8.50%. Owens & Minor has a consensus target price of $27.2778, suggesting a potential downside of 27.39%. Given Bausch Health Companies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bausch Health Companies is more favorable than Owens & Minor.

Profitability

This table compares Bausch Health Companies and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Owens & Minor-0.72%18.07%2.26%

Valuation & Earnings

This table compares Bausch Health Companies and Owens & Minor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.24$-1,788,000,000.00$4.436.78
Owens & Minor$9.21 billion0.30$-62,370,000.00$0.5667.09

Owens & Minor has higher revenue and earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bausch Health Companies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Summary

Bausch Health Companies beats Owens & Minor on 10 of the 14 factors compared between the two stocks.

Owens & Minor (NYSE:OMI) and Canopy Growth (NASDAQ:CGC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Earnings & Valuation

This table compares Owens & Minor and Canopy Growth's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Owens & Minor$9.21 billion0.30$-62,370,000.00$0.5667.09
Canopy Growth$297.34 million35.73$-993,370,000.00$1.3221.06

Owens & Minor has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Owens & Minor and Canopy Growth, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Owens & Minor05402.44
Canopy Growth510211.94

Owens & Minor presently has a consensus price target of $27.2778, suggesting a potential downside of 27.39%. Canopy Growth has a consensus price target of $35.6778, suggesting a potential upside of 28.34%. Given Canopy Growth's higher possible upside, analysts clearly believe Canopy Growth is more favorable than Owens & Minor.

Profitability

This table compares Owens & Minor and Canopy Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Owens & Minor-0.72%18.07%2.26%
Canopy Growth-312.84%-13.11%-9.66%

Volatility & Risk

Owens & Minor has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500.

Institutional and Insider Ownership

73.0% of Owens & Minor shares are owned by institutional investors. Comparatively, 10.2% of Canopy Growth shares are owned by institutional investors. 2.2% of Owens & Minor shares are owned by company insiders. Comparatively, 0.3% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Owens & Minor beats Canopy Growth on 9 of the 15 factors compared between the two stocks.

Penumbra (NYSE:PEN) and Owens & Minor (NYSE:OMI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

88.2% of Penumbra shares are held by institutional investors. Comparatively, 73.0% of Owens & Minor shares are held by institutional investors. 8.9% of Penumbra shares are held by insiders. Comparatively, 2.2% of Owens & Minor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Penumbra and Owens & Minor's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$547.41 million19.14$48.46 million$0.98293.26
Owens & Minor$9.21 billion0.30$-62,370,000.00$0.5667.09

Penumbra has higher earnings, but lower revenue than Owens & Minor. Owens & Minor is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Penumbra and Owens & Minor, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Penumbra02402.67
Owens & Minor05402.44

Penumbra presently has a consensus target price of $279.00, suggesting a potential downside of 2.92%. Owens & Minor has a consensus target price of $27.2778, suggesting a potential downside of 27.39%. Given Penumbra's stronger consensus rating and higher probable upside, analysts plainly believe Penumbra is more favorable than Owens & Minor.

Risk & Volatility

Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Profitability

This table compares Penumbra and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Penumbra-1.79%-0.12%-0.09%
Owens & Minor-0.72%18.07%2.26%

Summary

Penumbra beats Owens & Minor on 8 of the 13 factors compared between the two stocks.

PRA Health Sciences (NASDAQ:PRAH) and Owens & Minor (NYSE:OMI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Risk & Volatility

PRA Health Sciences has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Valuation and Earnings

This table compares PRA Health Sciences and Owens & Minor's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PRA Health Sciences$3.07 billion3.41$243.02 million$4.8033.70
Owens & Minor$9.21 billion0.30$-62,370,000.00$0.5667.09

PRA Health Sciences has higher earnings, but lower revenue than Owens & Minor. PRA Health Sciences is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PRA Health Sciences and Owens & Minor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PRA Health Sciences16302.20
Owens & Minor05402.44

PRA Health Sciences presently has a consensus price target of $121.2857, indicating a potential downside of 25.02%. Owens & Minor has a consensus price target of $27.2778, indicating a potential downside of 27.39%. Given PRA Health Sciences' higher possible upside, equities research analysts plainly believe PRA Health Sciences is more favorable than Owens & Minor.

Insider & Institutional Ownership

96.1% of PRA Health Sciences shares are held by institutional investors. Comparatively, 73.0% of Owens & Minor shares are held by institutional investors. 1.3% of PRA Health Sciences shares are held by insiders. Comparatively, 2.2% of Owens & Minor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares PRA Health Sciences and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PRA Health Sciences7.09%22.21%7.04%
Owens & Minor-0.72%18.07%2.26%

Summary

PRA Health Sciences beats Owens & Minor on 10 of the 14 factors compared between the two stocks.


Owens & Minor Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ICON Public logo
ICLR
ICON Public
2.0$204.47-0.4%$10.96 billion$2.81 billion34.08Analyst Report
Increase in Short Interest
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$65.01-1.4%$10.81 billion$2.32 billion53.73
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.03-0.9%$10.68 billion$8.60 billion-5.51
Canopy Growth logo
CGC
Canopy Growth
1.0$27.80-1.4%$10.62 billion$297.34 million-8.32
Penumbra logo
PEN
Penumbra
1.5$287.39-0.4%$10.48 billion$547.41 million-1,064.41
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.4$161.76-0.0%$10.44 billion$3.07 billion47.30Increase in Short Interest
News Coverage
Henry Schein logo
HSIC
Henry Schein
1.7$71.17-0.4%$10.13 billion$9.99 billion17.53
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90-0.3%$9.51 billion$2.16 billion53.28Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.68-0.1%$9.45 billionN/A0.00Increase in Short Interest
Amedisys logo
AMED
Amedisys
1.2$282.96-0.4%$9.29 billion$1.96 billion56.71Insider Selling
News Coverage
Natera logo
NTRA
Natera
1.5$106.95-0.6%$9.26 billion$302.33 million-44.94Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.58-1.6%$9.13 billion$788.10 million103.85Analyst Upgrade
Increase in Short Interest
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73-1.0%$9.07 billion$1.45 billion19.27Analyst Report
Syneos Health logo
SYNH
Syneos Health
1.6$86.25-0.5%$8.99 billion$4.68 billion47.39Insider Selling
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$118.56-4.5%$8.94 billion$289.59 million-36.37
Encompass Health logo
EHC
Encompass Health
2.0$84.93-2.7%$8.43 billion$4.61 billion31.81
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.12-0.3%$8.21 billion$40.56 million-16.16
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$29.82-2.7%$8.04 billionN/A0.00Increase in Short Interest
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19-3.7%$8.01 billion$3.34 million-20.54Unusual Options Activity
News Coverage
Chemed logo
CHE
Chemed
2.2$479.76-2.4%$7.66 billion$1.94 billion29.09
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$81.17-4.0%$7.61 billion$10.68 million-44.11
Hill-Rom logo
HRC
Hill-Rom
1.8$114.56-0.5%$7.60 billion$2.88 billion34.51Increase in Short Interest
Sotera Health logo
SHC
Sotera Health
1.8$26.29-1.8%$7.44 billionN/A0.00Analyst Upgrade
Invitae logo
NVTA
Invitae
1.6$37.64-3.8%$7.40 billion$216.82 million-9.68Insider Selling
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$122.05-1.6%$7.39 billion$73.99 million-47.12Unusual Options Activity
Exelixis logo
EXEL
Exelixis
1.9$23.59-1.5%$7.36 billion$967.78 million49.15
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72-0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65-0.5%$7.02 billion$87.99 million-80.54News Coverage
Change Healthcare logo
CHNG
Change Healthcare
1.0$22.81-0.8%$6.99 billion$3.20 billion-41.47
Globus Medical logo
GMED
Globus Medical
1.4$69.75-0.1%$6.96 billion$785.37 million75.82News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90-0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Envista logo
NVST
Envista
1.1$42.52-1.4%$6.83 billion$2.75 billion-327.08Analyst Downgrade
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.41-0.5%$6.65 billion$195.99 million290.06Insider Selling
Twist Bioscience logo
TWST
Twist Bioscience
1.2$135.24-5.0%$6.58 billion$90.10 million-36.06Insider Selling
Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95-1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$54.01-3.8%$6.53 billion$26.68 million-24.44
Medpace logo
MEDP
Medpace
1.2$179.90-2.8%$6.48 billion$860.97 million55.02Insider Selling
News Coverage
LHC Group logo
LHCG
LHC Group
1.7$203.52-1.2%$6.43 billion$2.08 billion61.86Decrease in Short Interest
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78-2.3%$6.30 billion$150,000.00-21.12Unusual Options Activity
News Coverage
Gap Down
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$231.46-0.8%$6.29 billion$82.05 million-99.77
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$72.25-1.8%$6.11 billion$1.52 billion107.84Insider Selling
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$31.53-4.2%$6.09 billion$90.89 million-112.60Analyst Upgrade
Omnicell logo
OMCL
Omnicell
1.5$137.84-0.7%$5.95 billion$897.03 million158.44
Haemonetics logo
HAE
Haemonetics
1.6$116.97-1.4%$5.94 billion$988.48 million56.51
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$46.38-2.9%$5.94 billion$8.09 million-19.65Analyst Downgrade
Insider Selling
News Coverage
HealthEquity logo
HQY
HealthEquity
1.8$70.99-1.4%$5.89 billion$531.99 million1,420.08
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$114.89-0.7%$5.88 billionN/A-49.52
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$42.03-2.4%$5.85 billion$85.07 million-44.24Insider Selling
Tenet Healthcare logo
THC
Tenet Healthcare
1.0$54.42-2.3%$5.79 billion$18.48 billion-418.62Upcoming Earnings
Decrease in Short Interest
NeoGenomics logo
NEO
NeoGenomics
1.5$49.34-0.4%$5.78 billion$408.83 million-1,644.12Analyst Report
News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.